Condition: Advanced Malignancies · Sponsor: Novartis Pharmaceuticals
This drug-drug interaction (DDI) study aims to evaluate the impact of pelabresib at steady-state plasma concentrations on the pharmacokinetic (PK) profile of A) a single dose of repaglinide and a single dose of midazolam, and B) a single dose of combined drospirenone and ethinyl estradiol. The study will be conducted in adult participants with advanced malignancies for whom no standard or curative treatment options are available.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Novartis Pharmaceuticals · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Candiolo, TO, Italy | Recruiting |
| Novartis Investigative Site | Pozuelo de Alarcón, Madrid, Spain | Recruiting |
| Novartis Investigative Site | Barcelona, Spain | Recruiting |
| Novartis Investigative Site | Madrid, Spain | Recruiting |
| Novartis Investigative Site | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07340190